Mẫu số 01-B

CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY

Số: 640 /CV-DHT

CỘNG HÒA XÃ HỘI CHỦ NGHĨA VIỆT NAM

Độc lập - Tự do - Hạnh phúc

Hà Nội, ngày 28 tháng 07 năm 2026

CÔNG BỐ THÔNG TIN ĐỊNH KỲ BÁO CÁO TÀI CHÍNH

Kính gửi: Sở Giao dịch Chứng khoán Hà Nội

Thực hiện quy định tại Khoản 3 Điều 14 Thông tư số 96/2020/TT-BTC ngày 16/11/2020 của Bộ Tài chính hướng dẫn công bố thông tin trên thị trường chứng khoán, CTCP Dược phẩm Hà Tây thực hiện công bố thông tin báo cáo tài chính (BCTC) quý 2/năm 2026 với Sở Giao dịch Chứng khoán Hà Nội như sau:

1. Tên tổ chức: CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY

- Mã chứng khoán: DHT
- Địa chỉ: Số 10A phố Quang Trung, phường Hà Đông, TP. Hà Nội
- Điện thoại liên hệ/Tel: 0433 501 117 Fax:
- Email: duochatay@gmail.com
- Website: https://www.hataphar.com.vn

2. Nội dung thông tin công bố:

- BCTC quý 2/năm 2026

[X] BCTC riêng (TCNY không có công ty con và đơn vị kế toán cấp trên có đơn vị trực thuộc);

[X] BCTC hợp nhất (TCNY có công ty con);

[ ] BCTC tổng hợp (TCNY có đơn vị kế toán trực thuộc tổ chức bộ máy kế toán riêng).

- Các trường hợp thuộc diện phải giải trình nguyên nhân:

+ Tổ chức kiểm toán đưa ra ý kiến không phải là ý kiến chấp nhận toàn phần đối với BCTC (đối với BCTC được soát xét/được kiểm toán):

[ ] Có [X] Không

Văn bản giải trình trong trường hợp tích có:

[ ] Có [ ] Không

+ Lợi nhuận sau thuế trong kỳ báo cáo có sự chênh lệch trước và sau kiểm toán từ 5% trở lên, chuyển từ lỗ sang lãi hoặc ngược lại (đối với BCTC được kiểm toán năm 2026):

[ ] Có [X] Không

Văn bản giải trình trong trường hợp tích có:

☐ Có ☐ Không

+ Lợi nhuận sau thuế thu nhập doanh nghiệp tại báo cáo kết quả kinh doanh của kỳ báo cáo thay đổi từ 10% trở lên so với báo cáo cùng kỳ năm trước:

☒ Có ☐ Không

Văn bản giải trình trong trường hợp tích có:

☒ Có ☐ Không

+ Lợi nhuận sau thuế trong kỳ báo cáo bị lỗ, chuyển từ lãi ở báo cáo cùng kỳ năm trước sang lỗ ở kỳ này hoặc ngược lại:

☐ Có ☒ Không

Văn bản giải trình trong trường hợp tích có:

☐ Có ☐ Không

Thông tin này đã được công bố trên trang thông tin điện tử của công ty vào ngày: 28/07/2026 tại đường dẫn: https://www.hataphar.com.vn/thong-tin-codong.html3.

3. Báo cáo về các giao dịch có giá trị từ 35% tổng tài sản trở lên trong năm 2026: Không có

Trường hợp TCNY có giao dịch đề nghị báo cáo đầy đủ các nội dung sau:

- Nội dung giao dịch:

- Tỷ trọng giá trị giao dịch/tổng giá trị tài sản của doanh nghiệp (%) (*căn cứ trên báo cáo tài chính năm gần nhất*):

- Ngày hoàn thành giao dịch

Chúng tôi xin cam kết các thông tin công bố trên đây là đúng sự thật và hoàn toàn chịu trách nhiệm trước pháp luật về nội dung các thông tin công bố.

Đại diện tổ chức
Người đại diện theo pháp luật/Người UQCBTT
(Ký, ghi rõ họ tên, chức vụ, đóng dấu)

CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY

TỔNG GIÁM ĐỐC
OSAMU YOMOGIDA

Tài liệu đính kèm:
- BCTC riêng Quý 2.2026
- BCTC HN Quý 2.2026
- Văn bản giải trình

HATAPHAR
CÔNG TY CP DƯỢC PHẨM HÀ TÂY

No.:638/CV-BCTC-DHT

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

Hanoi, July 28, 2026

To: The State Securities Commission of Viet Nam
Hanoi Stock Exchange

Company name: Ha Tay Pharmaceutical Joint Stock Company
Stock Code: DHT
Head office: 10A Quang Trung – Ha Dong Ward – Hanoi City
Phone: 0433 501 117 – Fax: 0433 829 054
Information disclosure officer: Mrs. Pham Minh Thu – Deputy Manager of Legal and Communications Department.

In the Consolidated financial statements for Q2 2026, the business results of Hatay Pharmaceutical Joint Stock Company are as follows:

The total profit after tax in Q2 2026 was VND 11.409.975.718, compared to VND 13.408.687.822 in Q2 2025 — a decrease of VND 1.998.712.104, equivalent to a drop of 14.91% This was mainly due to:

- Gross profit in the Q2 in 2026 amounted to VND 51,319,928,919, compared to VND 51,099,341,904 in the Q2 in 2025, representing an increase of VND 220,587,015.
- Financial income in the Q2 in 2026 amounted to VND 4,640,393,405, compared to VND 5,660,632,622 in the Q2 in 2025, representing a decrease of VND 1,020,239,217, or 18.02%. The decline in financial income had an adverse impact on the Company's profit for the period.
- Selling expenses and general and administrative expenses in the Q2 in 2026 totaled VND 40,945,408,110, compared to VND 36,921,558,738 in the Q2 in 2025, representing an increase of VND 4,023,849,372, or 11%. The increase in selling expenses and general and administrative expenses negatively affected the Company's profit for the period.
- Corporate income tax expense for the Q2 in 2026 amounted to VND 3,632,813,461, compared to VND 2,928,429,738 in the Q2 in 2025, representing an increase of VND 704,383,723, or 24%. The higher corporate income tax expense reduced the Company's profit after tax for the period.

We hereby report to the State Securities Commission of Vietnam and the Hanoi Stock Exchange for your information.

Recipient:
- As above
- Archive: Office files

HA TAY PHARMACEUTICAL JOINT STOCK COMPANY
General Director

M.S.D.N: 0500391400 C.T.C.P
CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY
P. HÀ ĐÔNG - TP. HÀ NỘI

Osamu Yomogida

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

CONSOLIDATED FINANCIAL STATEMENTS

For the period from 01/04/2026 to 30/06/2026

Form B 01 - DN/HN

CONSOLIDATED BALANCE SHEET

As at June 30, 2026

Unit: VND

	ASSETS	Codes	Notes	30/6/2026	01/01/2026 (Reclassification)
A -	**CURRENT ASSETS**	**100**		**689,600,287,571**	**896,739,416,323**
I.	**Cash and cash equivalents**	**110**	**V.01**	**64,785,701,868**	**84,407,566,361**
1	Cash	111		49,285,701,868	74,036,751,569
2	Cash equivalents	112		15,500,000,000	10,370,814,792
II.	**Short-term financial investments**	**120**		**102,549,534,200**	**153,045,424,635**
1	Held-to-maturity investments	123	V.02	102,549,534,200	153,045,424,635
III.	**Short-term receivables**	**130**		**154,489,106,973**	**145,889,465,780**
1	Short-term trade receivables	131	V.03	115,370,564,562	111,636,095,800
2	Short- term advances to suppliers	132	V.04	42,456,270,278	37,840,076,173
3	Other short-term receivables	136	V.05	474,879,091	294,439,301
4	Provision for short-term doubtful debts	137	V.06	(3,812,606,958)	(3,881,145,494)
IV.	**Inventories**	**140**	**V.07**	**366,876,862,398**	**513,396,959,547**
1	Inventories	141		366,876,862,398	513,396,959,547
V.	**Current biological assets**	**150**		-	-
VI.	**Other current assets**	**160**		**899,082,132**	-
1	Deductible VAT	162		899,082,132	-
B -	**NON-CURRENT ASSETS**	**200**		**1,033,602,230,077**	**1,035,177,856,096**
I.	**Long-term receivables**	**210**		**6,407,042,500**	**6,407,042,500**
1	Other long-term receivables	215	V.05	6,407,042,500	6,407,042,500
II.	**Fixed assets**	**220**		**163,689,314,373**	**174,908,301,066**
1	Tangible fixed assets	221	V.08	162,312,654,373	173,531,641,066
	Cost	*222*		*444,246,675,571*	*446,492,048,355*
	Accumulated depreciation	*223*		*(281,934,021,198)*	*(272,960,407,289)*
2	Intangible fixed assets	227	V.09	1,376,660,000	1,376,660,000
	Cost	*228*		*2,026,660,000*	*2,026,660,000*
	Accumulated amortization	*229*		*(650,000,000)*	*(650,000,000)*
III.	**Non-current biological assets**	**230**		-	-
IV.	**Long-term assets in progress**	**240**		-	-
V.	**Construction work in progress**	**250**		**822,030,943,108**	**827,184,318,661**
1	Construction in progress	252	V.10	822,030,943,108	827,184,318,661
VI.	**Long-term financial investments**	**260**	**V.02**	**20,241,206,443**	**19,860,292,957**
1	Investment in joint-ventures, associates	262		20,241,206,443	19,860,292,957
VII.	**Other long-term assets**	**270**		**21,233,723,653**	**6,817,900,912**
1	Long-term prepayments expenses	271	V.11	20,190,389,980	5,632,174,250
2	Deferred tax assets	272	V.12	1,043,333,673	1,185,726,662
	TOTAL ASSETS (280=100+200)	**280**		**1,723,202,517,648**	**1,931,917,272,419**

Form B 01 - DN/HN

CONSOLIDATED BALANCE SHEET

As at June 30, 2026

(continued)

Unit: VND

	RESOURCES	Codes	Notes	30/6/2026	01/01/2026 (Reclassification)
C -	**LIABILITIES**	**300**		**592,225,826,665**	**820,716,628,095**
I.	**Current liabilities**	**310**		**505,670,679,118**	**734,022,780,548**
1	Short - term trade payables	311	V.13	209,312,093,810	261,260,793,034
2	Short - term advances from customers	312	V.14	105,646,454,510	177,983,077,668
3	Taxes and amounts payable to the State budget	314	V.15	3,321,108,060	5,515,053,039
4	Payables to employees	315		18,405,752,780	28,051,603,241
5	Short-term accrued expenses	316	V.16	96,289,965	161,520,303
6	Short-term unearned revenue	319	V.17	5,706,724,086	6,418,086,306
7	Other current payables	320	V.18	1,491,269,039	783,924,677
8	Short-term loans and obligations under finance	321	V.19	160,648,306,796	249,995,403,408
9	Bonus and welfare funds	323		1,042,680,072	3,853,318,872
II.	**Long-term liabilities**	**330**		**86,555,147,547**	**86,693,847,547**
1	Other long-term payables	338	V.18	3,486,900,000	3,625,600,000
2	Long-term loans and obligations under finance leases	339	V.19	83,068,247,547	83,068,247,547
D -	**EQUITY**	**400**		**1,130,976,690,983**	**1,111,200,644,324**
I.	**Owner's contributed capital**	**410**	**V.20**	**1,130,976,690,983**	**1,111,200,644,324**
1	Owner's contributed capital	411		905,755,510,000	905,755,510,000
-	*Ordinary shares carrying voting rights*	*411a*		*905,755,510,000*	*905,755,510,000*
2	Share premium	412		37,282,220,000	37,282,220,000
3	Other owners' equity	414		2,236,413,529	26,612,306,630
4	Treasury shares	415		(8,083,874,357)	(8,083,874,357)
5	Investment and development fund	418		10,749,248,213	10,749,248,213
6	Retained earnings	420		155,106,685,445	110,355,967,042
-	*Retained earnings accumulated to the prior year end*	*420a*		*134,116,766,080*	*56,699,133,435*
-	*Retained earnings of current year*	*420b*		*20,989,919,365*	*53,656,833,607*
7	Non-controlling interest	429		27,930,488,153	28,529,266,796
	TOTAL RESOURCES (440=300+400)	**440**		**1,723,202,517,648**	**1,931,917,272,419**

Hanoi, July 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by	Chief Accountant	General Director
Nguyen Hai Trieu	Dinh Nam Ha	Osamu Yomogida

CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY

Form B 02 - DN/HN

CONSOLIDATED INCOME STATEMENT

For the period from 01/04/2026 to 30/06/2026

Unit: VND

	ITEMS	Codes	Notes	Quarter II		Year 2026	Year 2025
				Year 2026	Year 2025		
1	**Gross revenue from goods sold and services rende**	**01**	**II.1**	**575,939,699,624**	**574,560,123,544**	**1,144,796,344,712**	**1,070,569,562,879**
2	Deductions	02	II.2	19,904,762	209,032,070	48,975,762	209,869,070
3	**Net revenue from goods sold and services rendere (10=01-02)**	**10**	**II.3**	**575,919,794,862**	**574,351,091,474**	**1,144,747,368,950**	**1,070,359,693,809**
4	Cost of sales	11	II.4	524,599,865,943	523,251,749,570	1,054,639,682,733	963,034,045,601
5	**Gross profit from goods sold and services rendere (20 =10-11)**	**20**		**51,319,928,919**	**51,099,341,904**	**90,107,686,217**	**107,325,648,208**
6	Gain/(loss) on sale and disposal of investment property	21		-	-	-	-
7	Financial income	22	II.5	4,640,393,405	5,660,632,622	12,186,945,882	16,272,793,859
8	Financial expenses	23	II.6	3,390,334,927	9,447,239,102	6,527,240,650	13,245,813,064
	In which: Interest expense	*24*		*2,880,294,497*	*3,430,297,452*	*5,758,663,193*	*7,127,225,787*
9	Selling expenses	25	II.9	11,199,570,753	8,431,676,250	23,709,341,492	15,716,331,981
10	General and administration expenses	26	II.9	29,745,837,357	28,489,882,488	53,649,843,979	60,775,790,178
11	Profit or loss from associates, joint ventures	27		342,963,379	2,156,368,964	996,007,549	4,989,433,485
12	**Operating profit {30 = 20 + (21 - 22) + 24 - (25 + 26)}**	**30**		**11,967,542,666**	**12,547,545,650**	**19,404,213,527**	**38,849,940,329**
13	Other income	31	II.7	3,479,113,615	3,790,770,741	7,119,670,306	7,453,240,653
14	Other expenses	32	II.8	771,185,302	1,198,831	775,105,726	630,379,075
15	**Profit from other activities (40=31-32)**	**40**		**2,707,928,313**	**3,789,571,910**	**6,344,564,580**	**6,822,861,578**

16	**Accounting profit before tax (50=30+ 40)**	**50**		**14,675,470,979**	**16,337,117,560**	**25,748,778,107**	**45,672,801,907**
17	Current CIT expense	51	II.10	3,632,813,461	2,928,429,738	5,215,244,396	8,352,860,985
18	Deferred CIT expense	52		(367,318,200)	-	142,392,989	-
19	**Net profit after corporate income tax (60=50-51-52)**	**60**		**11,409,975,718**	**13,408,687,822**	**20,391,140,722**	**37,319,940,922**
20	The Parent company's net profit after tax	61		11,942,377,166	13,185,055,359	20,989,919,365	34,485,901,629
21	The non-controlling interests shareholders' net profit a	62		(532,401,448)	223,632,463	(598,778,643)	2,834,039,293

Hanoi, July 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by	Chief Accountant	General Director
Nguyen Hai Trieu	**Dinh Nam Ha**	**Osamu Yomogida**

CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY
M.S.D.N: 0500391400 - C.T.C.P * P. HÀ ĐÔNG - TP. HÀ NỘI *

Form B 03 - DN/HN

CONSOLIDATED CASH FLOWS STATEMENT

(Under indirect method)

For the period from 01/04/2026 to 30/06/2026

Unit: VND

ITEMS	Codes	Notes	Quarter II - Year 2026	Quarter II - Year 2025	Year 2026	Year 2025
I. Cash flow from operating activities						
1. Profit before tax	*01*		***14,675,470,979***	***16,337,117,560***	***25,748,778,107***	***45,672,801,907***
2. Adjustments for						
- Depreciation of fixed assets and investment properties	02		6,183,282,936	5,948,299,520	12,360,112,693	11,930,613,214
- Provisions	03		(68,538,536)	212,849,489	(68,538,536)	212,849,489
- Foreign exchange loss/gain arising from translating foreign currency items	04		(987,481,174)	5,299,727,203	(987,481,174)	5,299,727,203
- Gain, loss from investing activities	05		(6,971,513,342)	(2,888,899,506)	(4,342,388,324)	(12,925,105,580)
- Interest expense	06		2,880,294,497	3,430,297,452	5,758,663,193	7,127,225,787
3. Profit from operating activities before changes in working capital	*08*		***15,711,515,360***	***28,339,391,718***	***38,469,145,959***	***57,318,112,020***
- Increases/Decreases in receivables	09		(14,963,326,798)	(62,448,659,751)	(9,430,184,789)	8,970,502,024
- Increases/Decreases in inventories	10		20,277,828,629	904,263,033	146,520,097,149	(23,684,158,516)
- Increases/Decreases in payables (excluding interest payable, corporate income tax payable)	11		17,075,889,945	98,272,860,270	(134,427,096,080)	98,493,753,748
- Increases/Decreases in prepayment expense	12		(2,055,441,299)	214,748,378	(1,598,308,200)	259,256,417
- Interest expense paid	14		(8,496,391,772)	(2,502,407,445)	(5,823,893,531)	(7,173,238,312)
- Corporate income tax paid	15		(2,142,955,532)	(5,424,431,247)	(6,693,175,871)	(10,494,507,962)
- Other cash inflows	16		(148,700,000)	-	-	-
- Other cash outflows	17		(137,440,000)	(177,662,877)	(2,810,638,800)	(178,962,877)
Net cash flow from operating activities	*20*		***25,120,978,533***	***57,178,102,079***	***24,205,945,837***	***123,510,756,542***
II. Cash flow from investing activities						
1. Acquisition and construction of fixed assets and other non-	21		866,307,482	(19,315,893,497)	(8,947,657,977)	(40,457,863,446)
2. Proceeds from sale, disposal of fixed assets and other non-	22		-	63,636,364	-	113,636,364

3. Cash outflows for lending, buying debt instruments of other	23		(120,000,000,000)	(10,000,000,000)	(120,000,000,000)	(70,000,000,000)
4. Cash recovered from lending, selling debt instruments of other	24		80,000,000,000	80,000,000,000	170,000,000,000	90,000,000,000
5. Cash recovered from lending, selling debt instruments of other entities	26		-	-	-	8,000,000,000
6. Interest earned, dividends and profits received	27		4,210,723,652	1,976,625,554	4,528,180,065	3,262,039,654
Net cash flow from investment activities	***30***		***(34,922,968,866)***	***52,724,368,421***	***45,580,522,088***	***(9,082,187,428)***
III. Cash flow from financial activities						
1. Proceeds from borrowing	33		65,472,759,527	221,332,140,167	208,735,041,876	381,263,054,367
2. Repayment of borrowing	34		(129,375,279,434)	(237,891,759,730)	(298,082,138,488)	(428,844,873,182)
5. Dividends and profits paid	35		-	-	-	-
Net cash flow from financial activities	***40***		***(63,902,519,907)***	***(16,559,619,563)***	***(89,347,096,612)***	***(47,581,818,815)***
Net cash flow in the period (50 = 20+30+40)	**50**		**(73,704,510,240)**	**93,342,850,937**	**(19,560,628,687)**	**66,846,750,299**
Cash and cash equivalents at the beginning of the year	**60**		**138,480,633,122**	**63,773,572,235**	**84,336,751,569**	**90,269,672,873**
Effect of changes in foreign exchange rates	61		9,578,986	657,432	9,578,986	657,432
Cash and cash equivalents at the end of the year (70 = 50+60+61)	**70**	**I.01**	**64,785,701,868**	**157,117,080,604**	**64,785,701,868**	**157,117,080,604**

Hanoi, July 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by	Chief Accountant	General Director
Nguyen Hai Trieu	**Dinh Nam Ha**	**Osamu Yomogida**

M.S.D.N: 0500391400 C.T.C.P * CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY * P. HÀ ĐÔNG - TP. HÀ NỘI

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

I. Additional information of items presented in the Consolidated Balance Sheet

1. Cash and cash equivalents

	30/6/2026	01/01/2026
	VND	**VND**
Cash	**49,285,701,868**	**74,036,751,569**
Cash on hand	***5,337,046,561***	***5,265,522,207***
Cash in bank	***43,948,655,307***	***68,771,229,362***
VND	43,691,064,659	68,646,493,402
USD	246,815,342	113,685,066
EUR	10,775,306	11,050,894
Cash equivalents (*)	**15,500,000,000**	**10,370,814,792**
Bank deposits with terms of less than 3 months	15,500,000,000	10,370,814,792
Total	**64,785,701,868**	**84,407,566,361**

(*) Represents deposit contracts with maturities of no more than three months placed with Viet A Commercial Joint Stock Bank – Ha Dong Branch.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

2. Financial investments

a) Held-to-maturity investments

	30/6/2026			01/01/2026 (Reclassification)		
	Cost	**Recoverable amount**	**Provision**	**Giá gốc**	**Recoverable amount**	**Provision**
Vietnam Joint Stock Commercial Bank for Industry and Trade - Thanh	-	-	-	81,904,219,178	81,904,219,178	-
Viet A Joint Stock Commercial Bank – Ha Dong Branch (2)	81,763,232,830	81,763,232,830	-	30,546,356,141	30,546,356,141	-
Vietnam Technological and Commercial Joint Stock Bank – Dong Do Branch (3)	20,786,301,370	20,786,301,370	-	40,594,849,316	40,594,849,316	-
Total	**102,549,534,200**	**102,549,534,200**	-	**153,045,424,635**	**153,045,424,635**	-

(1) Pursuant to Term Deposit Agreement No. 320/2025/21810 dated 3 July 2025, the Company placed a term deposit of VND 80 billion with a term of six months, bearing interest at 4.8% per annum, with interest payable at maturity.

(2) Comprises term deposit agreements with a six-month maturity, bearing interest at rates ranging from 8.0% to 8.7% per annum, with interest payable at maturity.

(3) Pursuant to Term Deposit Agreement No. 14588888368035/TGKH/TCB dated 7 January 2026, the Company placed a term deposit of VND 20 billion with a term of six months, bearing interest at 8.2% per annum, with principal and interest payable at maturity.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

b) Capital contribution into other entities

	30/6/2026 VND			01/01/2026 VND		
	Cost	**Adjustments during the period**	**Carrying amount**	**Cost**	**Adjustments during the period**	**Carrying amount**
Investment into subsidiaries						
Southern Hataphar Company Limited (i)	700,000,000	256,814,139	956,814,139	700,000,000	124,961,667	824,961,667
Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company (ii)	2,450,000,000	16,834,392,304	19,284,392,304	2,450,000,000	16,585,331,290	19,035,331,290
Total	**3,150,000,000**	**17,091,206,443**	**20,241,206,443**	**3,150,000,000**	**16,710,292,957**	**19,860,292,957**

Summary of the operating performance of subsidiaries and associates during the year

(i) According to the 13th Amendment to the Enterprise Registration Certificate dated 18 November 2025, the Company invested VND 700,000,000 in Hataphar Southern Company Limited, representing 48.28% of its charter capital. As of the end of the reporting period, the Company's investment remained VND 700,000,000, equivalent to 48.28% of the investee's charter capital.

(ii) According to the 5th Amendment to the Enterprise Registration Certificate dated 7 April 2026, the Company invested VND 9,800,000,000 in Hataphar Healthcare Vietnam High-Tech Pharmaceutical Joint Stock Company, representing 49% of its charter capital. As of the end of the reporting period, the Company held 49% of the investee's charter capital, equivalent to 980,000 shares of Hataphar Healthcare Vietnam High-Tech Pharmaceutical Joint Stock Company.

The associates have continued their normal business operations, with no significant changes compared with the previous reporting period.

As at 30 June 2026, the fair values of all the above investments could not be determined because there were no quoted market prices, or sufficient information was not available to reliably measure their fair values. Accordingly, the fair values of these investments may differ from their carrying amounts.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

3. Trade receivable

		30/6/2026 VND		01/01/2026 VND	
		Amount	Provision	Amount	Provision
a)	**Short-term**	**115,370,564,562**	**(3,100,934,958)**	**111,636,095,800**	**(3,169,473,494)**
	- Some large balances in trade receivables:				
	Thanh Vinh Pharmaceutical and Medical Materials JSC	675,300,780	-	148,639,650	-
	Thuan Anh Pharmaceutical Company Limited	1,090,011,240	-	5,779,512,102	-
	Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	22,792,015,259	-	40,103,925,920	-
	Phap Au Pharmaceutical JSC	1,396,865,418	-	892,019,757	-
	Duc Tam Company Limited	2,144,721,711	-	2,739,541,083	-
	Vinh Gia Pharmaceutical JSC	2,905,018,231	-	1,064,753,077	-
	Truong Huy Company Limited	3,896,430,151	-	2,969,374,918	-
	Davinci – France Pharmaceutical Joint Stock	4,353,752,300	-	3,188,089,888	-
	Danh Minh Pharmaceutical Joint Stock Company	5,681,272,550	-	3,780,248,320	-
	Vinaplant Pharmaceutical JSC	7,671,070,464	-	6,973,025,318	-
	Stabled Pharmaceutical Company Limited	1,605,899,700	-	884,881,615	-
	Kim Long Investment JSC	1,186,387,324	-	1,657,733,296	-
	Thu Duc City Hospital	1,774,525,000	(1,671,860,000)	1,774,525,000	(1,671,860,000)
	T&T Equipment Joint Stock Company	3,517,653,670	-	9,799,671,420	-
	Life Pharmaceutical and Medical Equipment Joint	-	-	1,738,670,425	-
	Quang Cường Pharmaceutical Joint Stock Company	-	-	8,019,153,310	-
	Dong Do Pharmaceutical Company Limited	27,868,489,018	-	-	-

4. Advances to suppliers

		30/6/2026 VND	01/01/2026 VND
a)	**Short-term**	**42,456,270,278**	**37,840,076,173**
	- Some large balances in Advances to suppliers:		
	Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	773,730,167	1,830,521,186
	Pharmametícs products a division of max Biocare	12,586,762,100	2,573,704,006
	Delta Pharma Ltd	1,516,328,464	7,846,059,364
	Inbiotech l.t.d	646,177,815	6,997,520,425
	Saifen Drugs Philippines Inc	3,584,185,500	2,840,549,628
	Blis pharma distribution and Consultancy corp.	11,973,124,900	3,384,715,680

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

5. Other receivables

	30/6/2026 VND		01/01/2026 VND	
	Amount	Provision	Amount	Provision
a) Short - term	**474,879,091**	-	**294,439,301**	-
Other receivables	***131,935,186***	-	***163,462,990***	-
Advances	***342,943,905***	-	***130,976,311***	-
Nguyen Van Phuc	100,000,000	-	-	-
Others	242,943,905	-	130,976,311	-
b) Long - term	**6,407,042,500**	-	**6,407,042,500**	-
Mortgages, deposits	***6,407,042,500***	-	***6,407,042,500***	-
Management Board of Hoa Lac High-Tech Park	6,407,042,500	-	6,407,042,500	-
Total	**6,881,921,591**	-	**6,701,481,801**	-

6. Bad debts

	30/6/2026 VND		01/01/2026 VND	
	Cost	Recoverable amount	Cost	Recoverable amount
Total value of receivables, that are overdue and difficult to recover				
Accounts receivable	***3,460,368,948***	***359,433,990***	***3,539,882,618***	***370,409,124***
Thu Duc City Hospital	1,774,525,000	102,665,000	1,774,525,000	102,665,000
Others	1,685,843,948	256,768,990	1,765,357,618	267,744,124
Advances to suppliers	***711,672,000***	-	***711,672,000***	-
ERP Solutions Joint Stock Company	711,672,000	-	711,672,000	-
Total	**4,172,040,948**	**359,433,990**	**4,251,554,618**	**370,409,124**

7. Inventories

	30/6/2026 VND		01/01/2026 VND	
	Cost	Provision	Cost	Provision
Purchased goods in transit	101,696,519,228	-	127,357,336,205	-
Raw materials	70,531,930,614	-	74,584,107,934	-
Tools and supplies	317,983,557	-	342,444,153	-
Work in progress	4,410,717,655	-	9,735,832,625	-
Finished goods	45,549,084,588	-	23,437,595,070	(1,961,049,751)
Goods	144,370,626,756	-	277,939,643,560	-
Total	**366,876,862,398**	-	**513,396,959,547**	**(1,961,049,751)**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

8. Increases, decreases in tangible fixed assets

Unit: VND

Items	Building and structures	Machinery, equipment	Means of transport, transmission equipment	Office equipment and tools	Other fixed assets	Total
Cost						
Balance as at 01/01/2026	**168,479,750,526**	**259,122,286,133**	**13,999,342,253**	**4,451,386,943**	**439,282,500**	**446,492,048,355**
Purchase in the year	-	1,152,439,000	-	-	138,687,000	**1,291,126,000**
Liquidation of fixed assets	-	(3,536,498,784)	-	-	-	**(3,536,498,784)**
Balance as at 30/06/2026	**168,479,750,526**	**256,738,226,349**	**13,999,342,253**	**4,451,386,943**	**577,969,500**	**444,246,675,571**
Accumulated depreciation						
Balance as at 01/01/2026	**101,863,548,983**	**159,583,502,688**	**7,103,561,805**	**3,970,511,312**	**439,282,500**	**272,960,407,289**
Depreciation in the year	3,652,956,964	8,139,146,657	496,454,151	71,554,921	-	**12,360,112,693**
Liquidation of fixed assets	-	(3,386,498,784)	-	-	-	**(3,386,498,784)**
Balance as at 30/06/2026	**105,516,505,947**	**164,336,150,561**	**7,600,015,956**	**4,042,066,233**	**439,282,500**	**281,934,021,198**
Net book value						
As at 01/01/2026	**66,616,201,543**	**99,538,783,445**	**6,895,780,448**	**480,875,631**	-	**173,531,641,066**
As at 30/6/2026	**62,963,244,579**	**92,402,075,788**	**6,399,326,297**	**409,320,710**	**138,687,000**	**162,312,654,373**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

9. Increases, decreases in intangible fixed assets

Unit: VND

Items	Accounting software	Land use rights	Total
Cost			
Balance as at 01/01/2026	**650,000,000**	**1,376,660,000**	**2,026,660,000**
Balance as at 30/06/2026	**650,000,000**	**1,376,660,000**	**2,026,660,000**
Accumulated amortization			
Balance as at 01/01/2026	650,000,000	-	650,000,000
Balance as at 30/06/2026	**650,000,000**	**-**	**650,000,000**
Net book value			
As at 01/01/2026	**-**	**1,376,660,000**	**1,376,660,000**
As at 30/06/2026	**-**	**1,376,660,000**	**1,376,660,000**

10. Construction in progress

	30/6/2026 VND	01/01/2026 VND
Hataphar High-Tech Pharmaceutical Factory	814,748,939,426	807,746,227,200
Bioequivalent cost	-	1,277,777,778
Purchasing fixed assets	925,925,926	925,925,926
Factory Renovation	6,356,077,756	2,674,508,863
Cost of research and development of pharmaceutical products	-	14,559,878,894
Total	**822,030,943,108**	**827,184,318,661**

11. Prepayments

	30/6/2026 VND	01/01/2026 VND
Long-term		
Issued tools and instruments awaiting for allocation	2,049,108,501	2,465,920,534
Cost of research and development of pharmaceutical products	12,959,907,530	-
Repair and renovation costs	4,959,151,727	2,858,499,091
Other Prepayments	222,222,222	307,754,625
Total	**20,190,389,980**	**5,632,174,250**

12. Deferred tax assets

	30/6/2026 VND	01/01/2026 VND
Corporate income tax rates are used to determine the value of deferred income tax assets.	20%	20%
Deferred income tax assets relate to deductible temporary differences.	1,043,333,673	1,185,726,662
Total	**1,043,333,673**	**1,185,726,662**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

13. Trade payables

	30/6/2026 VND		01/01/2026 VND	
	Amount	**Amount able to be paid off**	**Amount**	**Amount able to be paid off**
Short - term	**209,312,093,810**	**209,312,093,810**	**261,260,793,034**	**261,260,793,034**
- Some large balances in Trade payables:				
Dong Au Trading and Production Company Limited	1,239,317,982	1,239,317,982	3,979,856,644	3,979,856,644
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	4,480,596,669	4,480,596,669	5,817,834,883	5,817,834,883
KPC Pharmaceuticals, Inc	23,878,433,717	23,878,433,717	19,025,983,320	19,025,983,320
Wockhardt Limited	24,663,029,725	24,663,029,725	10,056,600,528	10,056,600,528
XL Laboratories PVT.,LTD	-	-	22,359,757,441	22,359,757,441
Pharmaunity Co.,Ltd	-	-	13,349,510,483	13,349,510,483
Pharmametics products a division of max Biocare	36,767,484,671	36,767,484,671	13,799,528,479	13,799,528,479
Delta Pharma Ltd	53,462,671,565	53,462,671,565	35,828,249,950	35,828,249,950
Blis pharma distribution and Consultancy corp.	-	-	40,758,864,060	40,758,864,060

14. Advances from customers

	30/6/2026 VND	01/01/2026 VND
Short - term	**105,646,454,510**	**177,983,077,668**
- Some large balances in Advances from customers:		
T&T Equipment Joint Stock Company	3,555,140,357	790,000,000
T&T Trading and Pharmaceutical Joint Stock Company	7,141,708,000	6,442,145,755
Thuan An Phat Pharmaceutical Joint Stock Company	-	10,784,000,000
Dong Do Pharmaceutical Company Limited	-	2,502,291,750
TB Vietnam Pharmaceutical Trading Company Limited	22,261,120,350	49,761,555,583
Vietlife Pharmaceutical Joint Stock Company	-	3,117,958,640
Hieu Anh Pharmaceutical Company Limited	9,616,136,453	8,045,259,000
Lam An Pharmaceutical Trading Company Limited	-	6,509,000,000
Tan Dai Cat Pharmaceutical Company Limited	2,151,864,000	-
Life Pharmaceutical and Medical Equipment Joint Stock Company	7,294,910,000	7,278,056,310
Dai Song Duong Biopharmaceutical Company Limited	7,898,230,375	9,028,478,251
California USA Pharmaceutical Company Limited	11,141,778,005	5,753,424,645
French Pharmaceutical Joint Stock Company	1,399,623,012	28,976,548,644

15. Taxes and amounts payable to the State budget

Unit: VND

Items	01/01/2026	Payable during the year	Paid during the year	30/6/2026
Payables				
Value added tax for domestic	841,144,007	8,549,361,579	9,351,599,336	38,906,250

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

Items	01/01/2026	Payable during the year	Paid during the year	30/6/2026
Value added tax for import	-	38,887,044,652	38,887,044,652	-
Import and Export tax	-	4,927,630,446	4,927,630,446	-
Corporate income tax	4,550,220,339	5,215,244,396	6,693,175,871	3,072,288,864
Personal income tax	123,688,693	2,579,910,743	2,493,686,490	209,912,946
Land and housing tax, and land	-	101,203,055	101,203,055	-
Natural resource tax	-	11,926,600	11,926,600	-
Land rental fee	-	2,108,400,847	2,108,400,847	-
Total	**5,515,053,039**	**62,380,722,318**	**64,574,667,297**	**3,321,108,060**

16. Accrued expenses

	30/6/2026 VND	01/01/2026 VND
Short-term		
Interest payable	96,289,965	161,520,303
Total	**96,289,965**	**161,520,303**

17. Unearned revenue

	30/6/2026 VND	01/01/2026 VND
a) Short-term		
Deferred rental income from the lease of buildings and premises	658,524,989	575,370,229
Unrealised profit relating to inventories not yet sold to external parties by an associate arising from intercompany sales transactions	5,048,199,097	5,842,716,077
Total	**5,706,724,086**	**6,418,086,306**

18. Other payables

	30/6/2026 VND	01/01/2026 VND
a) Short-term	**1,491,269,039**	**783,924,677**
Insurance payables	441,612,917	592,397,733
Others	1,049,656,122	191,526,944
b) Long-term	**3,486,900,000**	**3,625,600,000**
Long term collaterals, deposits received	3,486,900,000	3,625,600,000
Total	**4,978,169,039**	**4,409,524,677**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

Form B 09a - DN/HN

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

19. Loans

	30/6/2026		In the period		01/01/2026	
	Amount	Amount able to be paid off	Increase	Decrease	Amount	Amount able to be paid off
a) Short-term	**160,648,306,796**	**160,648,306,796**	**208,735,041,876**	**298,082,138,488**	**249,995,403,408**	**249,995,403,408**
a1) Short-term borrowing	***146,803,598,871***	***146,803,598,871***	***208,735,041,876***	***298,082,138,488***	***236,150,695,483***	***236,150,695,483***
Vietnam Joint Stock Commercial Bank for Industry and Trade - Thanh An Branch	24,585,918,394	24,585,918,394	27,003,790,363	32,913,687,818	30,495,815,849	30,495,815,849
Joint Stock Commercial Bank For Foreign Trade Of Vietnam - West Hanoi Branch	26,712,876,010	26,712,876,010	43,712,034,371	79,311,770,320	62,312,611,959	62,312,611,959
Shinhan Bank Vietnam Limited - Hanoi Branch	28,365,590,146	28,365,590,146	67,966,495,110	91,651,765,953	52,050,860,989	52,050,860,989
Joint Stock Commercial Bank for Investment and Development of Vietnam - Ngoc Khanh Branch	25,886,584,460	25,886,584,460	39,059,765,677	37,583,085,462	24,409,904,245	24,409,904,245
Vietnam Bank for Agriculture and Rural Development- Ha Noi 2 Branch	19,791,268,800	19,791,268,800	21,118,721,175	22,160,803,244	20,833,350,869	20,833,350,869
Individuals	21,461,361,061	21,461,361,061	9,874,235,180	34,461,025,691	46,048,151,572	46,048,151,572
a2) Long-term loans on due date	***13,844,707,925***	***13,844,707,925***	-	-	***13,844,707,925***	***13,844,707,925***
MUFG Bank, Ltd., - Hanoi City Branch	13,844,707,925	13,844,707,925	-	-	13,844,707,925	13,844,707,925
b) Long-term	**83,068,247,547**	**83,068,247,547**	-	-	**83,068,247,547**	**83,068,247,547**
MUFG Bank, Ltd., - Hanoi City Branch	83,068,247,547	83,068,247,547	-	-	83,068,247,547	83,068,247,547
Total	**243,716,554,343**	**243,716,554,343**	**208,735,041,876**	**298,082,138,488**	**333,063,650,955**	**333,063,650,955**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

Form B 09a - DN/HN

20. Owner's equity

20.1 Movement in owner's equity

Unit: VND

Items	Owner's contributed capital	Share premium	Other capital	Treasury stock	Investment and development fund	Retained earnings	Non-controlling interest	Total
Balance as at 01/01/2025	**823,417,730,000**	**97,320,000,000**	**26,612,306,630**	**(8,083,874,357)**	**10,749,248,213**	**79,530,817,489**	**27,214,093,742**	**1,056,760,321,717**
Increase in Owner's Capital Contribution from Share Premium	60,037,780,000	(60,037,780,000)	-	-	-	-	-	-
Increase the owner's capital contribution from Retained earnings	22,300,000,000	-	-	-	-	(22,300,000,000)	-	-
Profit in the previous year	-	-	-	-	-	53,656,833,607	5,383,623,054	**59,040,456,661**
Decrease due to dividend distribution	-	-	-	-	-	-	(4,068,450,000)	**(4,068,450,000)**
Other decreases	-	-	-	-	-	(531,684,054)	-	**(531,684,054)**
Balance as at 31/12/2025	**905,755,510,000**	**37,282,220,000**	**26,612,306,630**	**(8,083,874,357)**	**10,749,248,213**	**110,355,967,042**	**28,529,266,796**	**1,111,200,644,324**
Transfer of Other Capital to Retained earnings accumulated to the prior year end (*)	-	-	(24,375,893,101)	-	-	24,375,893,101	-	-
Profit/Loss in this year	-	-	-	-	-	20,989,919,365	(598,778,643)	**20,391,140,722**
Other decreases	-	-	-	-	-	(615,094,063)	-	**(615,094,063)**
Balance as at 30/06/2026	**905,755,510,000**	**37,282,220,000**	**2,236,413,529**	**(8,083,874,357)**	**10,749,248,213**	**155,106,685,445**	**27,930,488,153**	**1,130,976,690,983**

(1) Transfer of Other Owners' Equity to Retained Earnings in accordance with Proposal No. 152/TTr-DHT dated 10 February 2026, which was approved under Resolution No. 219/NQ-DHT dated 30 March 2026 of the 2026 Annual General Meeting of Shareholders of Ha Tay Pharmaceutical Joint Stock Company.

(*) Carrying amount of shares in subsidiaries acquired from the parent company before 1 July 2015.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

20.2 Details of owner's equity

	30/6/2026 VND	01/01/2026 VND
Hanoi City Development Investment Fund	34,076,520,000	34,076,520,000
ASKA Pharmaceutical Co.,Ltd	362,727,620,000	362,727,620,000
Le Van Lo	50,819,900,000	50,819,900,000
Ngo Van Chinh	22,195,920,000	22,195,920,000
Hoang Van Tue	36,153,210,000	36,153,210,000
Le Viet Linh	57,441,840,000	57,441,840,000
Nguyen Thi Minh Hau	1,725,100,000	1,725,100,000
Le Anh Trung	33,718,720,000	33,718,720,000
Le Xuan Thang	35,205,290,000	35,205,290,000
Ngo Tuan Viet	5,500,000,000	5,500,000,000
Others	266,191,390,000	266,191,390,000
Total	**905,755,510,000**	**905,755,510,000**

20.3 Capital transactions with owners, dividend distribution and shared profit

	Quarter II/2026 VND	Quarter II/2025 VND
Owner's contributed capital	**905,755,510,000**	**823,417,730,000**
Contribution at the beginning of the period	905,755,510,000	823,417,730,000
Increase in the year	-	-
Contribution at the end of period	905,755,510,000	823,417,730,000
Paid dividend, shared profit	-	-

20.4 Shares

	30/6/2026 Shares	01/01/2026 Shares
Number of shares registered for issue	90,575,551	90,575,551
Number of shares issued to the public	90,575,551	90,575,551
- Ordinary shares	*90,575,551*	*90,575,551*
Number of shares buyback	1,513	1,513
- Ordinary shares	*1,513*	*1,513*
Number of outstanding shares in circulation	90,574,038	90,574,038
- Ordinary shares	*90,574,038*	*90,574,038*

An ordinary share has par value of VND 10,000

20.5 Dividends

Dividends declared after the end of the accounting period:

- Dividends declared on ordinary shares:
- Dividends declared on preferred stock: none

Unrecorded cumulative preferred stock dividends: none

21. Off Separate Balance Sheet items

	30/6/2026	01/01/2026
Foreign currencies		
USD	9,416.73	4,387.44
EUR	357.70	365.98

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

II. Additional information for items presented in the Consolidated Income Statement

1. Gross revenue from goods sold and services rendered

	Quater II/2026 VND	Quater II/2025 VND
Sale of finished goods	115,149,414,033	160,641,494,152
Sales of merchandises	460,790,285,591	413,918,629,392
Total	**575,939,699,624**	**574,560,123,544**

2. Deductions

	Quater II/2026 VND	Quater II/2025 VND
Returned goods	19,904,762	209,032,070
Total	**19,904,762**	**209,032,070**

3. Net revenue from goods sold and services rendered

	Quater II/2026 VND	Quater II/2025 VND
Net sale of finished goods	115,129,509,271	160,432,462,082
Net sales of merchandises	460,790,285,591	413,918,629,392
Total	**575,919,794,862**	**574,351,091,474**

4. Cost of goods sold

	Quater II/2026 VND	Quater II/2025 VND
Cost of finished goods sold	74,466,230,653	117,689,425,863
Cost of merchandise sold	449,567,134,513	405,028,419,586
Inventory disposal expenses	566,500,777	533,904,121
Total	**524,599,865,943**	**523,251,749,570**

5. Financial income

	Quater II/2026 VND	Quater II/2025 VND
Financial income incurred in the period	4,640,393,405	5,660,632,622
Total	**4,640,393,405**	**5,660,632,622**

6. Financial expenses

	Quater II/2026 VND	Quater II/2025 VND
Interest expense	2,880,294,497	3,430,297,452
Foreign exchange loss incurred during the period	510,040,430	6,016,941,650
Total	**3,390,334,927**	**9,447,239,102**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

7. Other income

	Quater II/2026 VND	Quater II/2025 VND
Other income incurred in the period	3,479,113,615	3,790,770,741
Total	**3,479,113,615**	**3,790,770,741**

8. Other expenses

	Quater II/2026 VND	Quater II/2025 VND
Other expenses incurred in the period	771,185,302	1,198,831
Total	**771,185,302**	**1,198,831**

9. Selling expenses and general administration expenses

		Quater II/2026 VND	Quater II/2025 VND
a)	Selling expenses incurred in the period	11,199,570,753	8,431,676,250
b)	General administration expenses incurred in the period	29,745,837,357	28,489,882,488
	Total	**40,945,408,110**	**36,921,558,738**

10. Current corporate income tax expenses

	Quater II/2026 VND	Quater II/2025 VND
Current corporate income tax expense based on taxable income for the current	3,632,813,461	2,928,429,738
Adjustment to current corporate income tax expense in respect of prior years	-	-
Total current corporate income tax expense	3,632,813,461	2,928,429,738

Hanoi, July 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by	Chief Accountant	General Director
Nguyen Hai Trieu	Dinh Nam Ha	Osamu Yomogida

M.S.D.N: 050... - C.T.C.P
CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY
P. HÀ ĐÔNG - TP. HÀ NỘI